pharmasset psi-938 and psi-7977 & hepc

It looks like BIT's Phase IIa clinical trial of BIT225 may have some competition. These are outstanding results from the Pharmasset product.

(http://www.fiercebiotech.com/story/analysts-jolted-pharmassets-stellar-data-combo-hep-c-treatment/2011-03-09)

Treatment with two oral drugs developed by Pharmasset resulted in 15 of 16, or 94%, of patients reporting undetectable levels of the hepatitis C virus after 14 days, according to interim results from a study released Monday.
These early data on the two Pharmasset drugs -- PSI-938 and PSI-7977 are the best reported to date by any company seeking to develop a new, all-oral therapy for hepatitis C. This Pharmasset effort is drawing even more attention because it potentially eliminates the need for patients to be treated with long-acting interferon, one of two drugs currently used to treat hepatitis C but which is difficult for patients to tolerate and causes many side effects.
Pharmasset shares rose 24% on Monday and were up another 8% to $66.92 on Tuesday.


bluebush